FDA Vaccines & Related Biological Products Advisory Committee
Executive Summary
Also scheduled to meet Nov. 12-13 at the Bethesda Holiday Inn, 8:30 a.m. First day, the committee will discuss "a pending license application for acellular pertussis vaccine" and clinical endpoints of therapeutic vaccines for HIV- infected individuals. Lederle's Acel-Immune, developed by Takeda, was recommended for approval by the committee on Jan. 29. Second day, the committee will "discuss studies on the Japanese encephalitis vaccine." The committee also will discuss the intramural research programs of CBER's Mycoplasma Lab and Immunology Labs. Closed session scheduled on Nov. 13 from 3-4:30 p.m....
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth